Results: Most patients developed onset of skinhypopigmentation within the first month of treatment and all of the patients experienced additional drug toxicity.
2
Methods: In this case series, the authors describe unique clinical findings of skinhypopigmentation in six patients with CML who were treated with imatinib mesylate.
3
Conclusion: Skinhypopigmentation is a benign side effect from imatinib mesylate treatment that appears to be reversible upon discontinuation or dose reduction.